Christian Kollmannsberger

Also affiliated with University of British Columbia

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 19 papers. Top paper: “Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial”.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

European Urology Oncology(2024)10.1016/j.euo.2023.11.016

N/A

0.543DataRank · unranked

11 citations

Alice Dragomir, Lori A. Wood, Christian Kollmannsberger, Naveen S. Basappa, Anil Kapoor +15 more

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial

BMJ Oncology(2024)10.1136/bmjonc-2023-000181

N/A

0.536DataRank · unranked

8 citations

Yu‐Wei Chen, Martin H. Voss, Bradley A. McGregor, Mehmet Asım Bilen, Marc‐Oliver Grimm +9 more

Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy

Cancer Medicine(2022)10.1002/cam4.4644

N/A

0.489DataRank · unranked

25 citations

Matthew R. Trendowski, Emma Wilkinson, Mohammad Shahbazi, Paul C. Dinh, Megan M. Shuey +14 more

Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12063

N/A

0.165DataRank · unranked

2 citations

Annika Faucon, Matthew R. Trendowski, Mark J. Ratain, Paul C. Dinh, Darren R. Feldman +12 more

Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5016

N/A

0.165DataRank · unranked

2 citations

Sophie D. Fosså, Robert Huddart, Patrick O. Monahan, Chunkit Fung, Yiqing Song +13 more

The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12092

N/A

0.104DataRank · unranked

1 citations

Paul C. Dinh, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Chunkit Fung +8 more

Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e24066

N/A

0.104DataRank · unranked

1 citations

Megan M. Shuey, Mohammad Shahbazi, Matthew R. Trendowski, Paul C. Dinh, Darren R. Feldman +10 more

Factors associated with longitudinal progression of the cumulative burden of morbidity and overall mortality after cisplatin-based chemotherapy for testicular cancer

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf014

N/A

0DataRank · unranked

3 citations

Paul C. Dinh, Patrick O. Monahan, Timothy E. Stump, Chunkit Fung, Howard D. Sesso +11 more

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial

Kidney Cancer Journal(2021)10.52733/kcj19n3-a1

N/A

0DataRank · unranked

6 citations

Qian Yang, Andrea Carmack, Shiqi Zhang, Wen‐Chi Foo, Tim Eisen +15 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5025

N/A

0DataRank · unranked

2 citations

Paul C. Dinh, Patrick O. Monahan, Sophie D. Fosså, Robert Huddart, Chunkit Fung +11 more

Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12004

N/A

0DataRank · unranked

2 citations

Matthew R. Trendowski, Emma Wilkinson, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn +10 more

Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2682

N/A

0DataRank · unranked

13 citations

Heather E. Wheeler, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn +6 more

Data from Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

(2023)10.1158/1078-0432.c.6529577

N/A

0DataRank · unranked

0 citations

Heather E. Wheeler, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn +6 more

Data from Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors

(2023)10.1158/1078-0432.c.6529577.v1

N/A

0DataRank · unranked

0 citations

Heather E. Wheeler, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn +6 more